Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism
Extended anticoagulation treatment of ≥3 months with apixaban was associated with lower rates of recurrent VTE, MB, and CRNMB compared with LMWH in adults with cancer-associated VTE.
Authors
- Alexander T. Cohen (ORCID: https://orcid.org/0000-0002-9398-4621)
- Amol D. Dhamane
- Robert Stellhorn
- Jane Wang (ORCID: https://orcid.org/0000-0003-3705-3993)
- Risho Singh
- Xuejun Liu (ORCID: https://orcid.org/0000-0003-3787-3537)
- Xuemei Luo (ORCID: https://orcid.org/0000-0002-4448-4882)
- Stella Han
Institutions
- University of North Carolina at Chapel Hill (US)
- Pfizer (United States) (US)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Vencore (United States) (US)
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2024-08-01
- DOI
- https://doi.org/10.6004/jnccn.2024.7016
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.85